Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today

Monopar Therapeutics Inc MNPR shares are trading higher by 108% to $4.99 Thursday morning after the company announced early data from its ongoing open-label MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial confirming MNPR-101-Zr’s tumor targeting ability in humans.

What Happened: Monopar Therapeutics says MNPR-101, a humanized monoclonal antibody targeting uPAR-expressing cancers, demonstrated specific and durable uptake in metastatic tumors on PET scans, compared to standard FDG imaging.

Monopar’s COO, Andrew Cittadine, expressed satisfaction with the findings, and the company aims to further explore MNPR-101’s therapeutic potential in its upcoming Phase 1 trial in Australia.

Lead investigator Rodney Hicks highlighted the promising retention of MNPR-101-Zr in known disease sites. Monopar plans to present additional data at the European Association of Nuclear Medicine Congress in October 2024 and is set to launch a therapeutic trial with MNPR-101-Lu later this year.

Read Also: Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday

How To Buy MNPR Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Monopar Therapeutics’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, MNPR has a 52-week high of $8.65 and a 52-week low of $1.37.